KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Kyverna Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.83+0.16 (+2.82%)
Close on Oct 19, 2026
- Market cap
- $355.03M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.80 (−12.07%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $355.03M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.14
- Dividend yield
- –
- Free cash flow yield
- -43.30%
Fundamentals
- Net income
- -$152.64M
- EPS, diluted
- -$2.94
- Free cash flow
- -$153.72M
- Book value per share
- $2.72
- Diluted shares
- 61M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$158.93M
Net income
-$152.64M
EPS, diluted
-$2.94
Free cash flow
–
Reported periodTrailing twelve months